Evofem Biosciences Inc, (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, has enrolled the first patient in its pivotal Phase three clinical trial assessing the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhoea in women, it was reported on Tuesday.
EVOGUARD is a double-blind, placebo-controlled Phase three clinical trial aimed at assessing the safety and efficacy of the product intended for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoea infection in women.
The study is to enrol 1,730 women who have had a urogenital chlamydia or gonorrhoea infection at any time over the 16 weeks preceding the enrolment visit, along with one or more risk factors for infection.
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Astellas to present VEOZAH (fezolinetant) data at Menopause Society 2025 Annual Meeting
Imaging Biometrics acquires Kirkstall to expand presence in advanced cell culture technologies
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference